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At Risk for Huntington's Disease
HD is a genetically caused brain disorder that causes uncontrollable bodily movements and robs
people's ability to walk, talk, eat, and think. The final result is a slow, ugly death. Children of parents
with HD have a 50-50 chance of inheriting the disease. There is no cure or treatment.
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WEDNESDAY, MAY 25, 2011

Holding the potential cure in my hand
After telling yet another audience of scientists about my family’s twodecade struggle against Huntington’s disease, I held a potential cure for
HD in my hand during a visit to Alnylam Pharmaceuticals in Cambridge,
MA, on May 17.
For me, it was like holding the most valuable substance in the world. I
inherited the HD-causing gene from my mother, who died of the disease in
2006 at the age of 68. At 51, I have now reached the age when HD started
destroying my mother’s brain, erasing her personality, and leaving her
unable to walk, talk, eat, or care for herself in the most basic way.
HD is 100 percent genetic: unless drug hunters get a treatment on the
market in the next few years, I will get symptoms.
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As I held what seemed like a magic compound, held in a small, securely
capped plastic container, I smiled. A treatment – and maybe even a cure –
now seemed more possible than ever. And Alnylam – along with its
partners Medtronic and the CHDI Foundation, Inc., the so-called “cure
Huntington’s disease initiative – is indeed preparing intensively to start a
clinical trial.
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A shot of me holding the potential cure (photo by Dr. Mathias Kretschmer
of Alnylam).
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This was a historic moment. As I stood in the lab at the Alnylam
(pronounced “al-NIGH-lam”) facility, I thought of all the years that our
community of affected families and treatment-seeking researchers had
waited for scientific breakthroughs.
I, the gene-positive HD person, caught a glimpse of a future filled with
hope, even as I recognize that hope depends on further scientific
breakthroughs and long odds. In the drug industry, 90 percent of clinical
trials fail to produce a treatment.
ALN-HTT: white and flaky
“ALN-HTT” is the name Alnylam has given this candidate drug product,
which is a solution containing the drug substance, the term scientists use
for the active ingredient in drugs. It stands for “Alnylam” and “huntingtin,”
the name of both the gene and protein that, when defective, cause HD.
The substance – an “siRNA,” or small interfering RNA molecule – is white
and flaky.
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ALN-HTT in the hands of Dr. Muru Murugaiah, an Alnylam principal
scientist, in the company's lab (photo by Gene Veritas)
RNA interference (RNAi) was discovered in 1998 by Craig Mello and
Andrew Fire in C. elegans, a species of worm. By interfering with the
conversion of the genetic code into specific proteins, RNAi controls helps
control the expression of genes and prevents problems from occurring in
cells.
For their discovery, in 2006 Mello and Fire won the Nobel Prize in
Physiology or Medicine.
At the outset, they and other scientists thought RNAi could not occur in
mammals or humans.
Then, in the early 2000s, two teams of German scientists discovered that
RNAi did indeed exist in cultured human cells (cells outside the body). In a
presentation at the Dana Farber Cancer Institute this past January,
Alnylam demonstrated that RNAi also exists in humans.
Gene silencing
This process is also known as “gene silencing.” RNAi can turn off
practically any gene in the body. The discovery of RNAi virtually coincided
with the completion of the Genome Project, which identified every gene in
curehd.blogspot.com/2011/05/holding-potential-cure-in-my-hand.html
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the human body.
Immediately, scientists embarked on making siRNAs to turn off harmful
genes. Drug discovery companies in Europe and the United States sprung
up to explore this breathtaking technology, seen by many as the genesis of
a new, very large class of drugs for halting all kinds of disease.
Nobel laureate Phil Sharp started Alnylam in 2002. The company took its
name from the middle star in the belt of the constellation Orion. “The star
has a luminosity that is 250,000 greater than the sun, representative of the
potential strength that RNAi therapeutics could bring to bear in human
health,” the company states on its website.
No company has yet put an RNAi drug onto the market, but Alnylam is
hoping to be the first. The company has a staff of about 175 and partners
with large pharmaceuticals in the search for RNAi remedies. Last year
Alnylam ended a five-year partnership with Swiss pharmaceutical giant
Novartis, forcing Alnylam to lay off 25 employees, but Novartis continues
to pursue drug possibilities using Alnylam experimental treatments.
Alnylam has more than $300 million in cash to support its activities.
Alnylam research focuses on a range of diseases and conditions, including
liver cancers, respiratory syncytial virus infection (affecting the lungs and
breathing passages), ultra-high cholesterol, refractory anemia, and
transthyretin-mediated amyloidosis. It also facilitates research on
neglected tropical diseases. The company is working on five RNAi products
for genetic diseases and aims to have them in advanced stages of clinical
development by the end of 2015.
Aiming for a clinical trial
In 2005, Alnylam initiated a major Huntington’s disease research project,
aiming not only to address HD but also to develop techniques that might
prove useful against other neurological diseases. Because HD is 100
percent genetic, it provides an excellent test for the effectiveness of gene
silencing.
Alnylam intends to use ALN-HTT to silence the huntingtin gene so that
less huntingtin protein is produced to harm brain cells. If successful, the
treatment would save brain cells from dying and slow down and possibly
even reverse the course of Huntington’s disease.
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Model of how siRNA drugs work: click to enlarge (Alnylam image)
A number of research labs have already demonstrated safety and
effectiveness of this approach in transgenic mice that have HD-like
symptoms. In preliminary studies, it’s also safe in monkeys.
The next step is a big one. Alnylam, Medtronic, and CHDI are preparing to
apply in 2012 to the U.S. Food and Drug Administration (FDA) for
permission to conduct a Phase I clinical trial of ALN-HTT in humans.
Alnylam hopes to start the trial in a small number of HD patients once the
application is accepted.
The goal of Phase I studies in general is to demonstrate safety and
tolerability – that the drug does not cause adverse impacts. If successful,
Alnylam would then proceed to Phases II and III, which would be designed
to demonstrate the effectiveness of the drug.
Entering uncharted territory
This is all uncharted territory for the FDA, doctors, researchers, the
biotech industry, and investors. Safety for the test subjects is of the utmost
importance – but so is the need to find a treatment for those families
facing the horrors of HD.
Getting ALN-HTT into the brain is a major scientific and medical
challenge. Because of the blood-brain barrier, which protects the brain
against foreign substances, many drugs cannot get into the brain. So a
drug like ALN-HTT must be injected directly into the brain.
So, for the first time in history, doctors will attempt to treat a brain
condition by implanting a device into the skull in order to inject a siRNA
drug.
Doctors have already experimented with deep-brain stimulation by
implanting electrodes into the brains of patients with Parkinson’s,
epilepsy, dystonia, depression, and even HD, explained Dinah Sah, Ph.D.,
the head of the Alnylam HD team and Vice President of Research. The
procedure has shown some benefit in Parkinson’s, but no known effect yet
in HD.
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Dr. Dinah Sah, Vice President of Research and the head of the Alnylam
HD team (photo by Gene Veritas)
Recently a clinical trial demonstrated improvement in Parkinson’s patients
who received gene therapy in which a virus was used to transport the
genetic message into brain cells.
Physicians have also injected a cell growth stimulant (growth factor) into
the brains of Parkinson’s patients. This last approach is still under study.
Alnylam has partnered with Medtronic, a leading maker of medicinal
pumps, to devise a pump to be placed in the HD patients’ abdomens.
Doctors will run thin tubing under the skin from the pumps to a nodule at
the top of the patients’ heads, and from that point a very fine needle will
run into the putamen, one of the regions of the brain most devastated by
HD.
For all of this to happen, expert doctors in the procedure will conduct an
operation on the clinical trial participants. Doctors will then administer
ALN-HTT, which will be dissolved in a special solution, by filling the pump
and allowing it to send the drug to the brain according to a schedule and in
doses to be determined by the researchers.
Other possibilities
This is all just a very brief sketch of the Alnylam project. Soon I will be
writing more detailed reports, which will examine how Alnylam and its
partners developed ALN-HTT and hope to turn it into a successful drug to
treat Huntington’s disease. These reports will also consider the many
challenges involved in this quest for an siRNA treatment.
Remember, too, that Alnylam is not the only project seeking to control HD
at its genetic roots. As I have noted in several articles since 2008, Isis
Pharmaceuticals, Inc., of Carlsbad, CA, has devised a similar drug
candidate to be applied directly in the brain (click here to read more). And
Dr. Jan Nolta’s lab at the University of California, Davis, is experimenting
with ways to use stem cells to introduce siRNA into the brain. For an
overview of HD and gene silencing, see the excellent article by Dr. Jeff
Carroll.
Isis and Alnylam operate a joint venture, Regulus Therapeutics, to
research microRNAs, an even more recent discovery also involving RNA
interference.
HD researchers aren’t banking on any one of these initiatives as the sole
solution to HD. Although one of them could indeed turn out to be the
“cure,” most researchers speak of the likely need for an HD “cocktail” of
drugs that would stop or at least reduce the many harmful effects on the
brain caused by HD.
Seeking patient input
To assist with the HD project, last November Alnylam signed an
agreement with CHDI, a multi-million-dollar effort backed by an
anonymous donor. CHDI is pumping money into the project and lending
its expertise in Huntington’s disease.
The crucial CHDI collaboration will reinforce Alnylam’s efforts to design a
safe Phase I trial.
To that end, Alnylam is also seeking to learn more about the patients and
gene-positive people whom it hopes to benefit.
curehd.blogspot.com/2011/05/holding-potential-cure-in-my-hand.html
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After watching my keynote speech at CHDI’s Sixth Annual HD
Therapeutics Conference in Palm Springs, CA, on February 7, Dr. Sah
invited me to give a similar presentation at the company. My May 17 visit
inaugurated a new Alnylam initiative to involve patient advocates in order
to put a human face on the conditions they seek to alleviate.
During the Q & A after the speech, attended by about 50 people, Alnylam
executives and scientists were anxious to hear my opinion about several
aspects of clinical trials.
The desire to function normally
One scientist wanted to know what people affected by HD community
would consider to be a successful treatment. Obviously we all want a “cure”
that completely eliminates the disease, I responded. But short of that, we
need something that would at least allow us to continue to function
normally. If someone suffered from chorea (the shaking and trembling
caused by HD), a good drug would at least prevent that person from also
losing the ability to think and speak.
We also need a drug that would prevent HD from erasing an individual’s
personality by preventing the behavioral, emotional, and cognitive
problems. HD, I said, had stolen my mother’s personhood.
One doctor asked: what if we fail and no treatment results from this
experiment?
I responded that I recognized that failure is a part of science. You don’t
know if something will work unless you try it, and if it fails, then you know
it’s time to proceed to other alternatives.
However, I told the audience that I personally do not think about failure.
The project must succeed! At that, many people nodded enthusiastically,
and one of the executives said: “We agree with you!”
At that moment, I felt a special bond with everybody in the room. We were
all rededicating ourselves to the quest for the cure – although everybody
also recognized that failure remained a distinct possibility.
Avoiding hurdles, gaining speed
Afterwards I met with CEO John Maraganore, Ph.D., President and COO
Barry Greene, Dr. Sah, Doug Macdonald, Ph.D., of CHDI, and Jules
Greenwald, the development director for the Huntington’s Disease Society
of America (HDSA). I took the opportunity to interview Maraganore and
Greene.
Both stressed the need to prepare an effective Phase I application to the
FDA and to convince the agency of the urgency of getting an siRNA
treatment to HD patients.
“It’s important for us to have a dialogue, which includes patient advocates,
with the FDA and other regulatory agencies, so that they appreciate the
significant burden that the disease has on patients and their families,”
Greene said.
“I think they know the disease, but they don’t really know the face of the
disease,” Dr. Maraganore said.
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Barry Greene (left), Gene Veritas, John Maraganore, and Dinah Sah
Much of the upcoming discussion with the FDA will revolve around the
question of how fast Phase II and Phase III of the trial can go. If the FDA
requires an extremely long efficacy study – from seven to ten years – the
costs could become prohibitive and scare off funding sources, like
investors, Greene explained. For patients and success, “speed really
matters,” he said.
Another crucial question involves determining “endpoints.” In this case, an
endpoint would be an observable change in a specific symptom and/or a
change in the level of defective protein in the brain cells or some other
marker of the drug’s effects (biomarkers).
Measuring huntingtin protein levels would likely prove the quickest
endpoint, although it’s not clear if a lower level of huntingtin in humans
will diminish symptoms the way it has in mice.
“We … want to have a testing approach that doesn’t create undue hurdles
to the point where you actually make it so difficult to prove that something
is maximally safe and maximally effective,” said Dr. Maraganore in
summarizing the challenges. “So you want to have the right balance.
“The urgency? The need? I think you said it: You have more to lose now
than ever,” he continued, referring to my race against time as I await a
treatment. “That’s the level of urgency that needs to be put into this
equation in terms of how these medicines are developed. That can only be
said by a patient."
Hanging out with the scientists
My day at Alnylam was one of the most intense of my entire life. This
article doesn’t even scratch the surface of what I experienced.
But Alnylam also planned some relaxation.
curehd.blogspot.com/2011/05/holding-potential-cure-in-my-hand.html

7/12

11/16/21, 1:43 PM

At Risk for Huntington's Disease: Holding the potential cure in my hand

I enjoyed hanging out with the scientists at lunch and dinner, and I was
impressed by their humanity and openness to new and different
perspectives.
I had contemplated removing from my speech a mini-meditation exercise
involving a demonstration of deep breathing, and also my discussion of the
question of God, HD, and the Jesuit priest-scientist Teilhard de Chardin.
But I was glad I didn’t. To my great surprise and joy, Sara Nochur, Ph.D.,
the Vice President for Regulatory Affairs, had read Teilhard’s works, and
her husband had just completed a book on the topic of the link between
science and the transcendental and also knew Teilhard’s writings. As we
walked back in the rain to the office, Dr. Nochur and I compared notes on
meditation and breathing as coping mechanisms.
At dinner Martin Goulet, Ph.D., who handles non-clinical experiments in
the Alnylam lab, and I talked about our families. He has a girl about the
same age as my HD-free ten-year-old daughter.

Dr. Martin Goulet (right) at work on the Alnylam HD project (photo by
Gene Veritas)
Getting out the word on trials and the cause
Over the next few days, I excitedly told other people in the movement that
I had held ALN-HTT in my hand. I felt like an apostle spreading news of a
religious revelation.
My journey did not end at Alnylam. On May 18 I flew to New York City for
meetings with other leaders of the HD movement. That day I visited CHDI
headquarters in Manhattan, where communications director Simon Noble,
Ph.D., and I discussed at length ways of getting out the word about the
need for involvement in upcoming clinical trials.
On May 19, I spent most of the day at HDSA. I gave an informal talk to the
staff about my situation and advocacy. I also interviewed CEO Louise
Vetter, now in her third year at HDSA. In line with the theme of clinical
curehd.blogspot.com/2011/05/holding-potential-cure-in-my-hand.html
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trials, we discussed the HDSA Clinical Trial Ambassador program, which
will utilize experienced members of the HD community to promote
awareness about the trials and answer potential participants’ concerns.
On May 20, I traveled to Princeton, NJ, to interview scientists from
CHDI’s clinical trials division.
The visit began with an informal brainstorming session at the home of
Maria Beconi, Ph.D., the director for drug metabolism and
pharmacokinetics (how drugs are absorbed, distributed, and excreted from
the body).
After we consumed pizza, soft drinks, brownies, and cupcakes, Maria
introduced me. I thanked the team for its commitment to HD research and
explained that I was tracking the social history of the HD movement and
the work of the scientists towards treatments and a cure.
I’ll be writing more about this issue and the CHDI unit in a future article.
In New York I met up twice with my friend and “HD alter ego,” Norman
Oder, who edits this blog. We caught up on each other’s lives, and we
discussed strategies for broadening the message of the HD cause.
Alnylam: passionate about HD
In 2008, when I first studied the Isis HD project, I fantasized about
wearing a drug-injecting pump on my head. That was a somewhat
inaccurate fantasy, because the pump would not be located on the head
itself, but in the abdomen. Isis plans to use this kind of system. But even if
it were located on the head, I would gladly use it – or any other device in
any other location, for that matter.
Likewise, I would happily accept the implantation of an ALN-HTT pump in
my abdomen. My need to avoid HD far outweighs any potential
inconvenience caused by such devices.
I came away from Alnylam energized by its scientists’ seriousness,
intelligence, practicality, and commitment to stopping HD. “We are very
passionate about this disease and finding a cure for it,” Dr. Maraganore
told me at the end of our interview.
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Dr. John Maraganore (Alnylam photo)
Dr. Maraganore told me that Alnylam will likely call on me again, as well
as other patient advocates, to offer advice on the design of the clinical trial
and to put a human face on the disease for the FDA.
Holding the cure is not enough
During the Q &A after my speech and the interview with Maraganore and
Greene, I had an uneasy sensation in my gut. Alnylam’s scientists wanted
not only to learn about my personal struggle against HD: they also wanted
me to become involved in the strategizing for a clinical trial. I suddenly felt
myself taking on a new, challenging, and immense responsibility in my HD
advocacy. Though I have no training in science, I need to increase my
knowledge of HD, the research for treatments, and the clinical trial
process.
Dr. Maraganore observed that, as a result of Alnylam's new collaboration
with CHDI, the company was "smarter about what we need to do" to get
ALN-HTT into trials. "By being smarter, we're going to be faster," he
added.
I, too, felt a bit smarter after meeting the Alnylam team. And I need to get
even smarter as we all move together towards this potentially historic
treatment.
Holding the potential cure in my hands is just the beginning. I must do my
part to help get that cure into our patients and ultimately into me.
(Note: because Alnylam invited me to speak and visit its facility, the
company paid for my round-trip airfare to the East Coast, my hotel in
Cambridge, and meals related to the visit. I maintained the right to
express my opinion in this and other articles on the HD project. )
Posted by Gene Veritas at 7:32 PM
Labels: ALN-HTT , Alnylam , CHDI , clinical trial , cure , gene silencing , genepositive , genetic , Genome Project , huntingtin , Huntington's , Isis , mother ,
RNAi , siRNA , Teilhard , treatment
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8 comments:
Unknown said...
This is amazing! I'm with you all the way.--Lauren Holder
6:20 AM, May 26, 2011

EJ said...
Thank you for updating us with this important information and
giving hope for the HD community. E.J. Garner
10:54 PM, May 26, 2011

june Brown said...
Such amazing story, how proud you must be to have a possiable
cure for HD your hands.
11:54 PM, May 26, 2011

Dinah Sah said...
Thank you, Ken, for your memorable visit to Alnylam - it was
very impactful for us as well.
With best wishes,
-Dinah
3:21 PM, May 27, 2011

Tara Ziemann said...
I read and re-read and re-read and smile. I pray to God that
this is it. Thank you so much for sharing.
5:34 PM, May 27, 2011

Caroline said...
Thank you so much for laying out the science and the current
state of the research so clearly! Excellent post and as always,
may God be with you and bless your work.
7:50 AM, May 28, 2011

Anonymous said...
Gene
My father was recently diagnosed with HD. Do you have an
email address where I could as you a few question?
Aimee
You can email me at skrumshz (at) gmail (dot) com.
11:08 AM, May 28, 2011

Hellen said...
This is so interesting and exciting. I can actually feel some hope
again.
Thank you for sharing
Helen from Sweden
2:32 PM, May 28, 2011
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